Flora Yan1, Hong Li2, John R de Almeida3, John M Kaczmar4, Patrik Pipkorn5, Joseph Zenga6, Mary S Richardson7, David M Neskey1, Anand K Sharma8, Terry A Day1, Evan M Graboyes1,2. 1. Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA. 2. Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA. 3. Department of Otolaryngology-Head and Neck Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada. 4. Division of Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. 5. Department of Otolaryngology-Head and Neck Surgery, Washington University, St Louis, Missouri, USA. 6. Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 7. Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. 8. Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.
Abstract
OBJECTIVE: Pathologic extranodal extension (ENE) is an important adverse feature for human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), but the prognostic significance of microscopic ENE (ENEmi) and role of adjuvant concurrent chemoradiation (CRT) for ENEmi remain unclear. This study evaluates (1) the prognostic significance of ENEmi in HPV-negative HNSCC and (2) whether adjuvant CRT is associated with improved overall survival (OS) for these patients. STUDY DESIGN: Retrospective cohort study. SETTING: Commission on Cancer (CoC)-accredited facilities. METHODS: This retrospective cohort study included patients in the National Cancer Database from 2009 to 2015 with pathologic node-positive (pN+) HPV-negative HNSCC with either pathologic ENEmi or no ENE who had undergone margin-negative surgery. The association of ENEmi with OS was evaluated using Cox proportional hazard analyses. Analyses were repeated in patients with ENEmi receiving adjuvant therapy to evaluate the association of adjuvant CRT with OS. RESULTS: We included 5483 patients with pN+ HPV-negative HNSCC, of whom 24% had ENEmi. On multivariable analysis, ENEmi was associated with decreased OS relative to no ENE (adjusted hazard ratio [aHR], 1.43; 95% CI, 1.28-1.59). Among patients with ENEmi who received ≥60 Gy of adjuvant radiation therapy (RT) (n = 617), adjuvant CRT was not associated with improved OS relative to RT (aHR, 0.91; 95% CI, 0.66-1.27). CONCLUSION: For patients with HPV-negative HNSCC, pN+ with ENEmi is associated with worse OS than pN+ without ENE. However, for patients with ENEmi, concurrent CRT is not associated with improved OS relative to RT. The optimal adjuvant paradigm for ENEmi requires additional investigation.
OBJECTIVE: Pathologic extranodal extension (ENE) is an important adverse feature for human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), but the prognostic significance of microscopic ENE (ENEmi) and role of adjuvant concurrent chemoradiation (CRT) for ENEmi remain unclear. This study evaluates (1) the prognostic significance of ENEmi in HPV-negative HNSCC and (2) whether adjuvant CRT is associated with improved overall survival (OS) for these patients. STUDY DESIGN: Retrospective cohort study. SETTING: Commission on Cancer (CoC)-accredited facilities. METHODS: This retrospective cohort study included patients in the National Cancer Database from 2009 to 2015 with pathologic node-positive (pN+) HPV-negative HNSCC with either pathologic ENEmi or no ENE who had undergone margin-negative surgery. The association of ENEmi with OS was evaluated using Cox proportional hazard analyses. Analyses were repeated in patients with ENEmi receiving adjuvant therapy to evaluate the association of adjuvant CRT with OS. RESULTS: We included 5483 patients with pN+ HPV-negative HNSCC, of whom 24% had ENEmi. On multivariable analysis, ENEmi was associated with decreased OS relative to no ENE (adjusted hazard ratio [aHR], 1.43; 95% CI, 1.28-1.59). Among patients with ENEmi who received ≥60 Gy of adjuvant radiation therapy (RT) (n = 617), adjuvant CRT was not associated with improved OS relative to RT (aHR, 0.91; 95% CI, 0.66-1.27). CONCLUSION: For patients with HPV-negative HNSCC, pN+ with ENEmi is associated with worse OS than pN+ without ENE. However, for patients with ENEmi, concurrent CRT is not associated with improved OS relative to RT. The optimal adjuvant paradigm for ENEmi requires additional investigation.
Entities:
Keywords:
adjuvant therapy; extranodal extension; head and neck squamous cell carcinoma
Authors: Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Silke Tribius; Johanna Donner; Henning Pazdyka; Adrian Münscher; Alexander Gröbe; Cordula Petersen; Andreas Krüll; Pierre Tennstedt Journal: Head Neck Date: 2016-02-13 Impact factor: 3.147
Authors: Volkert B Wreesmann; Nora Katabi; Frank L Palmer; Pablo H Montero; Jocelyn C Migliacci; Mithat Gönen; Diane Carlson; Ian Ganly; Jatin P Shah; Ronald Ghossein; Snehal G Patel Journal: Head Neck Date: 2015-10-30 Impact factor: 3.147
Authors: Jay S Cooper; Qiang Zhang; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Robert Lustig; John F Ensley; Wade Thorstad; Christopher J Schultz; Sue S Yom; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-30 Impact factor: 7.038
Authors: Yi An; Henry S Park; Jacqueline R Kelly; John M Stahl; Wendell G Yarbrough; Barbara A Burtness; Joseph N Contessa; Roy H Decker; Matthew Koshy; Zain A Husain Journal: Cancer Date: 2017-03-21 Impact factor: 6.860
Authors: John R de Almeida; Tra Truong; Nazir Mohemmed Khan; Jie Susie Su; Jonathan Irish; Ralph Gilbert; David Goldstein; Shao Hui Huang; Brian O'Sullivan; Ali Hosni; Andrew Hope; John Waldron; Aaron R Hansen; Anna Spreafico; Lillian L Siu; Bayardo Perez-Ordonez; Wei Xu; Ilan Weinreb Journal: Oral Oncol Date: 2020-06-29 Impact factor: 5.337
Authors: Jeremy P Harris; Michelle M Chen; Ryan K Orosco; Davud Sirjani; Vasu Divi; Wendy Hara Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-04-01 Impact factor: 6.223